Journal Watch

Advances in treatment of Spinal Muscular Atrophy (SMA) has been topical for a number of years. As new treatment options continue to gain FDA approval, the “snowball effect” continues to bring new insights into SMA management. Changing phenotypes, need for earlier patient identification and carrier testing, additional treatment avenues and the shifting of more attention to the non-neuromuscular aspects of SMA and quality of life were in the past, overwhelmingly overshadowed by the devastating neuromuscular consequences of SMA. The 4 articles that we have selected address some of these issues. The articles in our review are...

Commentary Voloshyn Taras, MD PhD Assistant Professor Kozyavkin International Rehabilitation Clinic, Truskavets, Ukraine Karen Skjei, MD Associate Professor University of Texas-Austin, Dell Medical School, Austin, Texas Infantile spasms (IS) or as they are currently termed epileptic spasms (ES), are characterized by a brief contraction followed by flexor, extensor, or mixed movements. The incidence of IS ranges from 2 to 3.5 in 10,000 live births, with onset during the first year of ...